368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Adi Diab, Sandra P. D’Angelo, Mehmet Asım Bilen et al.|Regular and Young Investigator Award Abstracts|2020

Cited by 15